- Technology and Data
- Front End Sales and Marketing
- Allergy
- HIV
- Women's Health
- Migraine
- Compounding
- Continuous Glucose Monitoring
- Mental Health Awareness
- Veterinary Pharmacy
- CBD
- Infectious Disease
- Eye Health
- Digestive Health
- Biosimilars
- Influenza
- Shingles
- COPD Management
- Pediatrics
- Generics
- Pain Management
- COVID-19
- Immunization
- Oncology
- Anticoagulants
- Autoimmune Diseases
- Dermatology
- Diabetes
- Respiratory
- Heart Health
- Cardiovascular Clinical Consult
Dr. Reddy’s launches moxifloxacin HCl
Dr. Reddy’s Laboratories has launched moxifloxacin HCl tablets, 400 mg, a therapeutic equivalent generic version of Avelox on March 4, following FDA approval.
Dr. Reddy’s Laboratories has launched moxifloxacin HCl tablets, 400 mg, a therapeutic equivalent generic version of Avelox on March 4, following FDA approval.
This fluoroquinolone is indicated for the treatment of adults with community-acquired pneumonia, acute exacerbations of chronic bronchitis, acute bacterial sinusitis, complicated skin and skin structure infections, pelvic inflammatory disease, and complicated intra-abdominal infections.
The product carries a warning that fluoroquinolones are associated with an increased risk of tendinitis and tendon rupture for patients of any age. There is a further increased risk in patients over 60 years of age, those taking corticosteroids, and individuals with kidney, heart, or lung transplants. Fluoroquinolones should not be used in patients with a history of myasthenia gravis as the drugs may exacerbate muscle weakness.
The brand name product had $195 million in U.S. sales for 2013, according to IMS Health.
Dr. Reddy’s generic moxifloxacin tablets, 400 mg, is available in bottle counts of 30.
